Profile

Business Description

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors, including non-small cell lung cancer (NSCLC) and ovarian cancer.

Company Info

Headquarters
Suite 720 - 999 West Broadway
Vancouver, BC V5Z 1K5
Canada

Telephone:
604-629-5989

Fax:
604-608-5685

Email:
info@delmarpharma.com

Clinical Operations
3475 Edison Way
Suite R
Menlo Park, CA  94025
USA

Industry Classifications

Sector:
Healthcare

Industry:
Pharmaceuticals

NAICS:
HMO Medical Centers (621491)

SIC:
Hospital And Medical Service Plans (6324)